Aurobindo Pharma Limited
https://www.aurobindo.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Aurobindo Pharma Limited
Aurobindo’s Eugia Prepares For ‘Muted’ Growth In FY2025
While Eugia continues to look for ways to solve the future challenges amidst temporary plant closure, parent Aurobindo reported a “good” performance in FY2024, with expected continued growth, and gave an update on its Auro Peptides business and GLP-1s.
‘Pegfilgrastim, We Are Definitely Going To Take It To The US Market,’ Says Aurobindo
While outlining key dates for its biosimilars portfolio, Aurobindo remains confident in the US market stability for its products.
Biogen Buys Desired Growth In Immunology With $1.15bn Hi-Bio Deal
Known for its efforts in neurology, Biogen has been looking to make somewhat safer bets in immunology as it seeks to diversify and may achieve that with HI-Bio’s Phase III-ready felzartamab.
Aurobindo One Step Closer To Xolair Biosimilar Registration
With originator Xolair’s patents already expired or about to end next year, Aurobindo’s CuraTeQ is on track with its omalizumab biosimilar for regulatory filings in 2024/2025, following a Phase I trial completion.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
-
- Acrotech Biopharma, LLC
- APL
- Glaxo (India)
- TL Biopharmaceutical AG.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice